Pulmonary Fibrosis News and Research

RSS

Insilico Medicine leader shares AI-driven drug discovery insights in Shanghai and Dubai

Dr. Jue Wang, Head of Global Business Development at Insilico Medicine, has been invited to attend the China Healthcare Summit in Shanghai. On the afternoon of November 3 at 16:45, she will deliver a keynote speech in the panel titled: "THE COMMODITIZATION TRAP: WHO WINS WHEN EVERYONE HAS THE SAME AI?"

30 Oct 2026

Mayo Clinic enters new medical era with precure research

Mayo Clinic researchers are uncovering the earliest shifts in disease biology - long before symptoms appear - revealing how disease takes root and opening new possibilities to identify, predict and potentially prevent disease before symptoms develop.

30 Oct 2026

Qureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands

Qureight, an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced it has been selected by Celea Therapeutics as the imaging CRO to support Celea’s Phase 3 SURPASS-IPF clinical trial.

From Qureight 21 Oct 2026

Restoring cellular recycling helps the body clear harmful zombie cells

As we grow older, our bodies accumulate "zombie cells"-living cells that have stopped dividing or functioning normally-but linger in our tissues, contributing to chronic inflammation and age-related diseases.

5 Oct 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

10 Sep 2026

New AI model decodes chemical signals guiding embryonic cell development

As an embryo develops from a small cluster of stem cells, those once "blank slate" cells begin to take on more specialized roles like brain, liver, or muscle cells, and organize themselves into three-dimensional structures such as tissues and organs.

8 Sep 2026

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

7 Sep 2026

Insilico Medicine releases frontier AI models for drug discovery

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the release of a series of frontier specialist models for chemistry and biology, trained through its MMAI Gym for Science framework.

2 Sep 2026

Bacterial protein fragment corisin found to drive pulmonary fibrosis

A bacterial protein fragment called corisin drives the process of pulmonary fibrosis by infiltrating and disrupting the cell's quality-control system, researchers at the University of Illinois Urbana-Champaign and Mie University in Japan found in a new study.

2 Sep 2026

Specialized blood vessel cells found to actively drive lung fibrosis

Millions of people worldwide are affected by diseases that cause scarring of the lungs, often leading to breathing difficulties and reduced quality of life.

28 Aug 2026

FDA grants fast track designation to Insilico's AI-designed mesothelioma drug candidate

Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico's proprietary AI, has received Fast Track Designation (FTD) from the U.S.

29 Jul 2026

Discovery of lung protein offers hope for pulmonary fibrosis

Pulmonary fibrosis is a deadly disease where scar tissue grows in the lungs, making breathing more difficult. Approximately 2,170 Australians are diagnosed annually with idiopathic pulmonary fibrosis (IPF), a form of the disease with no known cause and very few treatments.

16 Jul 2026

GLP-1 drugs may reduce lung scarring from Long COVID in diabetic patients

GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well.

9 Jul 2026

Insilico Medicine highlights AI drug discovery progress at executive summit

Dr. Alex Aliper, Co-founder and President of Insilico Medicine, will attend the AI for Good Global Summit 2026 in Geneva, Switzerland, on July 7.

3 Jul 2026

New testing approach improves pulmonary fibrosis diagnosis and treatment

A new Mayo Clinic study shows that integrating telomere length evaluation and genetic testing into pulmonary care can significantly change how physicians diagnose and treat pulmonary fibrosis - in some cases even redirecting the course of care.

2 Jul 2026

Monoclonal antibody shows promise for treating acute respiratory distress syndrome

Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress syndrome, or ARDS.

30 Jun 2026

Study identifies fPRDM16 as target for age-related pulmonary fibrosis

A study published recently in Current Molecular Pharmacology has uncovered a key mechanism linking aging to persistent pulmonary fibrosis, identifying the transcriptional regulator fPRDM16 as a potential therapeutic target.

25 Jun 2026

Milken Institute and Ann Theodore Foundation fund early-career sarcoidosis research grants

The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), today announced that the Ann Theodore Foundation Learning Opportunities in Medicine and Sarcoidosis (ATF-LOMAS) grant program has committed its first cycle of funding, totaling US$600,000 to early-career faculty conducting biomedical research in sarcoidosis.

19 Jun 2026